# ZZ Protein Identification & Recovery Research

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Science Officer
**Purpose**: Define research strategy for identifying, recovering, and therapeutically utilizing misfolded ZZ Alpha-1 Antitrypsin proteinâ€”potentially revolutionary treatment approach beyond augmentation therapy

---

## ðŸ“‹ Table of Contents

1. [Research Overview](#research-overview)
2. [The ZZ Protein Problem](#the-zz-protein-problem)
3. [Current Treatment Limitations](#current-treatment-limitations)
4. [Research Hypothesis](#research-hypothesis)
5. [Scientific Approach](#scientific-approach)
6. [Therapeutic Strategies](#therapeutic-strategies)
7. [Research Partnerships](#research-partnerships)
8. [Clinical Development Pathway](#clinical-development-pathway)
9. [Timeline & Milestones](#timeline--milestones)
10. [Funding Strategy](#funding-strategy)

---

## Research Overview

### The Big Idea: Rescue the Trapped Protein

**Current Paradigm**:

- ZZ patients produce AAT protein (liver makes it)
- BUT: Protein misfolds (Z mutation causes structural abnormality)
- Misfolded protein gets stuck in liver (can't be secreted into blood)
- Result: Low circulating AAT (lung unprotected) + liver damage (toxic protein accumulation)

**Current Treatment**:

- Augmentation therapy (infuse normal AAT from donor plasmaâ€”replaces missing protein in lungs)
- Does NOT address liver disease (trapped protein still accumulating)
- Does NOT use patient's own protein (expensive, lifelong infusions needed)

**Revolutionary Approach**:

- **Identify trapped ZZ protein** in liver cells (can we detect it? tag it? track it?)
- **Rescue misfolded protein** (unfold and refold correctly? chaperone proteins?)
- **Enable secretion** (allow patient's own ZZ protein to escape liver, circulate to lungs)
- **Clear liver accumulation** (remove toxic aggregatesâ€”reverse liver damage)

**Potential Impact**:

- âœ… **Cure liver disease** (remove toxic proteinâ€”stop fibrosis, cirrhosis)
- âœ… **Restore lung protection** (patient's own AAT circulatesâ€”no more infusions)
- âœ… **One-time treatment?** (fix protein folding permanentlyâ€”vs. weekly infusions for life)

---

## The ZZ Protein Problem

### What is the Z Mutation?

**Genetics**:

- SERPINA1 gene (chromosome 14â€”encodes Alpha-1 Antitrypsin protein)
- Z mutation: Glu342Lys (glutamic acid â†’ lysine at position 342)
- Single amino acid change causes protein to misfold

**Protein Folding Defect**:

- Normal AAT (M variant): Folds correctly in liver ER (endoplasmic reticulum), secreted into blood
- Z AAT: Misfolds (abnormal loop structure), forms polymers (chains of stuck-together AAT molecules)
- Polymers trapped in ER (can't pass quality controlâ€”cell refuses to secrete defective protein)

**Consequences**:

- **Plasma deficiency**: Only 10-15% of normal AAT reaches blood (rest trappedâ€”ZZ patients have 10-20 mg/dL vs. 150+ mg/dL normal)
- **Liver toxicity**: Trapped polymers accumulate (inclusions visible on biopsyâ€”PAS+ globules), cause inflammation, fibrosis, cirrhosis (10-15% of ZZ patients)
- **Lung disease**: Unprotected from neutrophil elastase (enzyme that destroys lung tissueâ€”AAT normally inhibits it)

---

### Why ZZ Protein Matters

**Patient Impact**:

- 100,000 ZZ individuals in US (estimatedâ€”many undiagnosed)
- 50-70% develop lung disease (emphysema, COPDâ€”typically age 30-50)
- 10-15% develop liver disease (childhood cirrhosis, adult liver failure, hepatocellular carcinoma)
- Augmentation therapy helps lungs (replace missing AAT) but NOT liver (trapped protein still accumulating)

**Unmet Need**:

- No treatment for AATD liver disease (except liver transplantâ€”only option for end-stage cirrhosis)
- Pediatric AATD (5-10% develop severe neonatal cholestasisâ€”liver failure in infancy, liver transplant or death)
- Augmentation therapy expensive ($100K-$200K/yearâ€”lifelong burden)

**If We Could Rescue ZZ Protein**:

- Treat liver disease (clear toxic aggregatesâ€”prevent/reverse cirrhosis)
- Reduce/eliminate need for augmentation (patient's own AAT circulates)
- Cure vs. chronic management (one-time intervention vs. lifelong therapy)

---

## Current Treatment Limitations

### Augmentation Therapy: Replacement, Not Cure

**How It Works**:

- Purify normal AAT from donor plasma (pooled from thousands of donors)
- Infuse weekly (60 mg/kg IVâ€”raises plasma AAT to protective levels)
- Slows lung disease progression (reduces emphysema rate by ~30-40%)

**Limitations**:

- âœ… Helps lungs (replaces missing AAT in circulation)
- âŒ Doesn't fix liver (trapped ZZ protein still accumulatingâ€”liver disease progresses)
- âŒ Expensive ($100K-$200K/yearâ€”insurance battles, financial burden)
- âŒ Lifelong (weekly infusions foreverâ€”patient burden, compliance challenges)
- âŒ Doesn't use patient's protein (relying on donor supplyâ€”limited, expensive to purify)

---

### Liver Transplant: Last Resort

**When Needed**: End-stage cirrhosis, liver failure, hepatocellular carcinoma (10-15% of ZZ patients)

**What It Does**:

- Remove diseased ZZ liver, replace with healthy donor liver (M genotypeâ€”makes normal AAT)
- Cures BOTH lung and liver disease (new liver produces normal AATâ€”no more deficiency, no more toxic accumulation)

**Limitations**:

- âŒ Major surgery (high risk, 1-5% mortality, 30% complication rate)
- âŒ Lifelong immunosuppression (anti-rejection drugsâ€”infection risk, kidney damage, cancer risk)
- âŒ Donor shortage (20,000 need liver transplant/year in US, only 8,000 availableâ€”many die waiting)
- âŒ Only for end-stage disease (not preventiveâ€”liver must fail first)

---

### Gene Therapy: Promising but Incomplete

**Approaches in Development**:

- AAV gene therapy (insert normal M gene into liverâ€”cells produce normal AAT)
- CRISPR gene editing (edit Z mutation â†’ M mutation in liver cells)

**Status**: Clinical trials (Phase 1/2â€”safety, dose-finding)

**Limitations** (Even When Approved):

- âœ… Fixes lung disease (new cells produce normal AATâ€”circulates to lungs)
- âŒ Doesn't remove ZZ protein (old cells still have trapped proteinâ€”liver disease risk remains)
- âŒ Durability unclear (gene therapy may fade over yearsâ€”need repeat dosing?)
- âŒ Expensive (predicted $1M-$2M one-time costâ€”insurance coverage uncertain)

---

## Research Hypothesis

### Core Hypothesis: ZZ Protein is Recoverable

**Question**: Can we rescue misfolded ZZ protein (unfold, refold correctly, enable secretion)?

**Supporting Evidence**:

1. **Chemical Chaperones Work** (In Lab):
   - 4-Phenylbutyrate (4-PBA), Tauroursodeoxycholic acid (TUDCA) reduce ZZ polymer formation (in cell cultureâ€”not yet tested in humans)
   - Improve ER protein folding (help quality control system tolerate slightly misfolded proteins)

2. **Autophagy Enhancers Clear Polymers**:
   - Carbamazepine (anti-seizure drug) activates autophagy (cellular "garbage disposal"â€”clears protein aggregates)
   - Reduces ZZ polymer accumulation in mouse models (human trials not yet done)

3. **Some ZZ Protein IS Secreted**:
   - 10-15% of ZZ AAT reaches blood (rest trappedâ€”but some escape)
   - Suggests protein not 100% defective (minor rescue â†’ more escapes?)

4. **Temperature-Sensitive Rescue**:
   - Lower temperature (in labâ€”33Â°C vs. 37Â°C body temp) improves ZZ folding (more protein secreted)
   - Suggests folding is "on the edge" (small nudge could tip toward correct folding)

**Hypothesis**:

- Pharmacological intervention (small molecule drug, chaperone protein, gene therapy adjunct) can:
  - Improve ZZ folding (reduce polymer formationâ€”more protein folds correctly)
  - Enhance secretion (allow more ZZ AAT to reach circulationâ€”10% â†’ 30-50%?)
  - Clear existing polymers (autophagy, degradationâ€”reduce liver toxicity)

**If True**: ZZ patients could produce therapeutic levels of their own AAT (reduce/eliminate augmentation need) + prevent liver disease

---

## Scientific Approach

### Phase 1: ZZ Protein Detection & Tracking (Years 1-2)

**Objective**: Develop tools to visualize, quantify ZZ protein in liver cells

**Approaches**:

**1. Fluorescent Probes**:

- Design antibody or small molecule that binds ZZ polymers (not normal AATâ€”specific for misfolded form)
- Tag with fluorescent dye (green, redâ€”visible under microscope)
- Test in cultured cells (can we see ZZ accumulation? track over time?)
- Validate in mouse models (ZZ transgenic miceâ€”do we detect polymers in liver?)

**2. Mass Spectrometry**:

- Extract protein from liver tissue (biopsy or autopsy samplesâ€”ZZ patients)
- Identify ZZ-specific post-translational modifications (misfolded protein may have different glycosylation, ubiquitination)
- Quantify polymer vs. monomer (how much is trapped vs. correctly folded?)

**3. Live-Cell Imaging**:

- Transfect cells with ZZ-GFP fusion protein (ZZ AAT with green fluorescent protein attached)
- Watch protein fold, traffic through ER, get secreted (or trapped)
- Identify bottlenecks (where does folding fail? ER? Golgi? secretion pathway?)

**Deliverable**: ZZ detection assay (can measure ZZ polymer levels in liver, track changes with treatment)

**Budget**: $500K (reagents, mice, imaging equipment, personnel)

---

### Phase 2: Protein Rescue Screening (Years 2-3)

**Objective**: Identify drugs/compounds that improve ZZ folding, secretion, or clearance

**Approach**: High-throughput screening

**1. Cell-Based Assay**:

- Culture cells expressing ZZ AAT (HepG2 liver cell line or patient iPSCsâ€”induced pluripotent stem cells)
- Expose to drug library (10,000-50,000 compoundsâ€”FDA-approved drugs, natural products, experimental molecules)
- Measure AAT secretion (ELISAâ€”how much ZZ AAT released into culture medium?)
- Measure polymer accumulation (immunofluorescenceâ€”how much ZZ trapped in cells?)

**2. Hit Validation**:

- Top candidates (drugs that increase secretion >50% or reduce polymers >50%) tested in dose-response
- Mechanism studies (how does drug work? chaperone? autophagy? other pathway?)
- Cytotoxicity screening (ensure drug not toxic to liver cells)

**3. Animal Testing**:

- Test top 5-10 compounds in ZZ mouse models (PiZ transgenic miceâ€”express human ZZ AAT)
- Dose orally (once daily, 4 weeks)
- Measure plasma AAT (does it increase?), liver polymers (do they decrease?), liver enzymes (AST, ALTâ€”liver damage markers)

**Deliverable**: 3-5 lead compounds (candidates for human testing)

**Budget**: $2M (screening facility, compound library, mice, personnel)

---

### Phase 3: Mechanism Studies (Years 3-4)

**Objective**: Understand HOW lead compounds rescue ZZ protein (mechanism of action)

**Approaches**:

**1. Structural Biology**:

- X-ray crystallography or cryo-EM (electron microscopy) of ZZ AAT Â± drug
- Does drug bind to ZZ protein? Where? Change conformation?

**2. Chaperone Interaction Studies**:

- Co-immunoprecipitation (pull down ZZ protein, see what other proteins bound)
- Does drug recruit chaperones (BiP, calnexin, Hsp70â€”proteins that help folding)?

**3. Autophagy Pathway Analysis**:

- Western blots for autophagy markers (LC3, p62â€”increase = more autophagy)
- Electron microscopy (see autophagosomesâ€”organelles that degrade aggregated protein)

**4. Genetic Validation**:

- CRISPR knockout (delete candidate genesâ€”e.g., autophagy genes, chaperone genes)
- Does drug still work? If not, confirms mechanism

**Deliverable**: Mechanism-of-action paper (publish in Nature, Cell, Scienceâ€”establish scientific credibility)

**Budget**: $1M (structural biology, proteomics, molecular biology)

---

## Therapeutic Strategies

### Strategy 1: Pharmacological Chaperone (Small Molecule Drug)

**Concept**: Drug binds to ZZ protein, stabilizes correct fold, enables secretion

**Precedent**:

- Trikafta (cystic fibrosisâ€”corrects misfolded CFTR protein)
- Migalastat (Fabry diseaseâ€”stabilizes alpha-galactosidase enzyme)

**Development**:

- Identify chaperone drug (high-throughput screenâ€”Phase 2 above)
- Optimize chemistry (medicinal chemistryâ€”improve potency, reduce side effects)
- Test in animals (efficacy, safety)
- Human trials (Phase 1/2/3â€”standard drug development)

**Timeline**: 10-15 years (drug discovery â†’ FDA approval)

**Cost**: $50M-$100M (typical small molecule drug development)

**Advantages**:

- âœ… Oral pill (patient takes dailyâ€”convenient vs. weekly infusions)
- âœ… Potentially curative (if raises AAT to protective levelsâ€”no more augmentation)
- âœ… Treats liver disease (reduces polymer accumulationâ€”prevents cirrhosis)

**Challenges**:

- âŒ Long timeline (decade+ to market)
- âŒ May not fully rescue protein (might need combo with augmentationâ€”partial rescue)

---

### Strategy 2: Autophagy Enhancer (Repurposed Drug)

**Concept**: Drug activates autophagy (cellular degradation pathwayâ€”clears ZZ polymers from liver)

**Candidates** (Already FDA-Approved):

- **Carbamazepine** (anti-seizure drugâ€”activates autophagy, shown to reduce ZZ polymers in mice)
- **Rapamycin** (immunosuppressantâ€”potent autophagy inducer)
- **Metformin** (diabetes drugâ€”mild autophagy activation, very safe)

**Development**:

- Clinical trial (repurpose existing drugâ€”faster than new drug development)
- Enroll ZZ patients with liver disease (20-50 patientsâ€”Phase 2)
- Treat with drug (e.g., carbamazepine 400 mg twice dailyâ€”standard dose)
- Measure liver polymers (liver biopsy before/afterâ€”see if polymers decrease), liver enzymes (ALT, ASTâ€”improve?), plasma AAT (increase?)

**Timeline**: 3-5 years (repurposed drugâ€”skip preclinical, go straight to human trial)

**Cost**: $5M-$10M (clinical trial costs)

**Advantages**:

- âœ… Fast (drug already approvedâ€”just need new indication)
- âœ… Cheap (generic drugsâ€”carbamazepine $20/month)
- âœ… Treats liver disease (primary benefitâ€”clear toxic polymers)

**Challenges**:

- âŒ May not increase circulating AAT (clears polymers but doesn't rescue foldingâ€”liver improves, lungs not helped)
- âŒ Side effects (carbamazepineâ€”dizziness, drowsiness, drug interactions)

---

### Strategy 3: Gene Therapy + Polymer Clearance (Combination)

**Concept**: Gene therapy produces new normal AAT (fixes lung disease) + autophagy drug clears old ZZ polymers (fixes liver disease)

**Approach**:

- **Gene Therapy**: AAV-AAT (insert M geneâ€”liver cells produce normal AAT)
- **Plus Autophagy Drug**: Carbamazepine or rapamycin (clear ZZ polymers from cells still making ZZ protein)

**Rationale**:

- Gene therapy only corrects ~20-30% of liver cells (rest still make ZZâ€”polymers still accumulating)
- Combination clears old polymers (reverse existing liver damage) + prevents new accumulation

**Development**:

- Piggyback on existing gene therapy trials (companies: Applied Genetic Technologies, Modernaâ€”AAV-AAT trials ongoing)
- Add autophagy drug arm (gene therapy alone vs. gene therapy + carbamazepine)

**Timeline**: 5-7 years (leverage existing gene therapy, add drug arm)

**Cost**: $10M-$20M (combination trial)

**Advantages**:

- âœ… Treats both lung AND liver (gene therapy = lungs, autophagy = liver)
- âœ… Potentially curative (one-time gene therapy + short-term autophagy drug â†’ permanent fix)

**Challenges**:

- âŒ Complex (two therapiesâ€”harder to coordinate, regulatory approval)
- âŒ Expensive (gene therapy $1M-$2Mâ€”affordability issue)

---

### Strategy 4: ZZ-Specific AAT Replacement (Novel Biologics)

**Concept**: Engineer modified AAT that resists polymerization (still has Z mutation but doesn't aggregate)

**Approach**:

- Protein engineering (modify ZZ AATâ€”add stabilizing mutations, prevent polymer formation)
- Test in vitro (does modified ZZ fold better? secrete more?)
- Gene therapy delivery (insert modified ZZ geneâ€”patient's liver makes improved ZZ protein)

**Precedent**:

- Factor VIII engineering (hemophiliaâ€”improved protein stability)
- Insulin analogs (diabetesâ€”modified insulin with better pharmacokinetics)

**Timeline**: 10-15 years (protein engineering â†’ gene therapy â†’ clinical trials)

**Cost**: $50M-$100M

**Advantages**:

- âœ… Uses patient's own genetic sequence (modified ZZâ€”not foreign M protein)
- âœ… Potentially better (engineered ZZ might have improved propertiesâ€”longer half-life, higher activity)

**Challenges**:

- âŒ High risk (protein engineering unpredictableâ€”may not work)
- âŒ Regulatory complexity (FDA may require extensive safety testingâ€”modified protein is novel)

---

## Research Partnerships

### Academic Partnerships

**Target Institutions**:

- **University of Florida** (Mark Brantly, MDâ€”AATD researcher, liver disease expert)
- **NIH (NHLBI)** (David Perlmutter, MDâ€”ZZ protein folding expert)
- **Washington University** (Jeffrey Teckman, MDâ€”pediatric AATD liver disease)
- **Cambridge University UK** (David Lomas, MDâ€”discovered ZZ polymerization mechanism)

**Collaboration Model**:

- Foundation funds research (grants to academic labsâ€”$100K-$500K/project)
- Academics conduct research (protein folding, drug screening, mouse models)
- Foundation owns IP (or co-ownsâ€”negotiate case-by-case)
- Publish together (co-author papersâ€”Foundation gains scientific credibility)

---

### Pharmaceutical Partnerships

**Target Companies**:

- **CSL Behring, Grifols, Takeda** (make augmentation therapyâ€”interested in improving/replacing current therapy)
- **Applied Genetic Technologies, Moderna** (AATD gene therapy companiesâ€”could add polymer clearance strategy)
- **Denali Therapeutics, Alector** (protein misfolding companiesâ€”experience with Alzheimer's, Parkinson'sâ€”similar biology)

**Partnership Opportunities**:

1. **Co-Development**: Foundation discovers drug target/compound â†’ partner develops clinically
2. **Licensing**: Foundation licenses IP â†’ partner pays royalties (funds Foundation programs)
3. **Sponsored Research**: Partner funds Foundation research (in exchange for first right to license discoveries)

---

### Patient Registry Partnership

**Registry Use**:

- Foundation's AATD Patient Registry (see separate documentâ€”10,000 patients enrolled by Year 5)
- Use for:
  - **Clinical trial recruitment** (identify ZZ patients with liver diseaseâ€”trial eligibility)
  - **Natural history studies** (track ZZ patients over timeâ€”understand liver disease progression)
  - **Biospecimen collection** (blood, liver biopsyâ€”for research use)

**Value to Research**:

- Rapid recruitment (trials enroll in months vs. yearsâ€”registry pre-screens patients)
- Real-world data (understand disease outside clinical trialsâ€”complement RCT data)

---

## Clinical Development Pathway

### Phase 1: Repurposed Drug Trial (Years 3-5)

**Trial Design**:

- **Drug**: Carbamazepine (autophagy enhancerâ€”clear ZZ polymers)
- **Population**: ZZ patients with liver disease (elevated liver enzymes, liver biopsy showing polymers)
- **N**: 50 patients (25 drug, 25 placebo)
- **Duration**: 6 months (long enough to see liver changes)
- **Endpoints**:
  - Primary: Liver polymer reduction (biopsy before/afterâ€”quantify polymers by immunostaining)
  - Secondary: Liver enzymes (ALT, ASTâ€”improve?), plasma AAT (increase?), FibroScan (liver stiffnessâ€”fibrosis improve?)

**Outcome Scenarios**:

- **Success** (polymers reduce >30%, enzymes improve) â†’ Phase 3 trial (larger, seek FDA approval)
- **Partial Success** (polymers reduce, no clinical benefit) â†’ Refine approach (higher dose? longer duration? combination therapy?)
- **Failure** (no effect) â†’ Try different drug (rapamycin, metformin, other autophagy enhancer)

**Budget**: $5M

---

### Phase 2: Novel Drug Development (Years 5-10+)

**If Pharmacological Chaperone Discovered** (Phase 2 screening):

- IND Filing (FDAâ€”Investigational New Drug application)
- Phase 1 (safety, dose-findingâ€”50 healthy volunteers)
- Phase 2 (efficacy, safetyâ€”100 ZZ patients)
- Phase 3 (pivotal trialâ€”300 patients, placebo-controlled)
- FDA Approval (if successfulâ€”5-10% chance, typical for novel drugs)

**Timeline**: 10-15 years from discovery

**Budget**: $50M-$100M (Foundation unlikely to fund entirelyâ€”partner with pharma)

---

## Timeline & Milestones

### Year 1-2: Discovery Phase

**Milestones**:

- âœ… ZZ detection assay developed (track polymers in liver)
- âœ… High-throughput screen completed (10,000+ compounds tested)
- âœ… 5-10 lead compounds identified (increase secretion or reduce polymers in cells)
- âœ… Mouse studies initiated (test top compounds in ZZ mice)

**Budget**: $2.5M

---

### Year 3-4: Validation & Mechanism

**Milestones**:

- âœ… Lead compounds validated in mice (plasma AAT increase, liver polymers decrease)
- âœ… Mechanism of action determined (chaperone? autophagy? other?)
- âœ… Scientific publications (Nature, Cell, Scienceâ€”establish credibility)
- âœ… Clinical trial protocol developed (for repurposed drugâ€”carbamazepine)

**Budget**: $3M

---

### Year 5: First-in-Human Trial

**Milestones**:

- âœ… Clinical trial enrollment complete (50 ZZ patients with liver disease)
- âœ… 6-month treatment (carbamazepine or other autophagy enhancer)
- âœ… Endpoint data analyzed (liver polymers, enzymes, AAT levels)
- âœ… Results presented (ATS conference, published in AJRCCM or Hepatology)

**Budget**: $5M

---

### Year 7-10: Pivotal Trials & Approval

**If Phase 2 Successful**:

- âœ… Phase 3 trial (300 patients, multi-center)
- âœ… FDA submission (NDAâ€”New Drug Application)
- âœ… FDA approval (indication: AATD liver disease treatment)
- âœ… Market launch (drug available to all ZZ patients)

**Budget**: $20M-$50M (likely pharma-funded at this stage)

---

## Funding Strategy

### Foundation Funding (Early Stage)

**Years 1-5**: Foundation funds discovery, preclinical, early clinical ($10M total)

**Sources**:

- Major donors ($2M-$5M giftsâ€”"Your donation will discover cure for AATD liver disease")
- NIH grants (R01, R21â€”$500K-$2M/grant, competitive)
- Pharmaceutical company partnerships ($1M-$5Mâ€”sponsored research agreements)

---

### Partnership Funding (Late Stage)

**Years 5-10**: Pharma partner funds late-stage development ($50M-$100M)

**Structure**:

- Foundation licenses IP (drug target, compounds, clinical data)
- Partner pays:
  - **Upfront**: $5M-$10M (signing bonus)
  - **Milestones**: $20M-$50M (payments for achieving Phase 2 success, Phase 3 enrollment, FDA approval)
  - **Royalties**: 5-10% of sales (ongoing revenueâ€”fund Foundation programs in perpetuity)

**Partner Candidates**: CSL Behring, Grifols, Takeda (already in AATD spaceâ€”natural fit)

---

## Success Metrics

### Research Outputs

**Year 3**:

- 3-5 peer-reviewed publications (top-tier journalsâ€”Nature, Cell, Science, AJRCCM)
- 5-10 lead compounds identified (validated in mice)

**Year 5**:

- Clinical trial data (50 patients treated, results published)
- Patent filings (3-5 patentsâ€”protect drug candidates, assays, methods)

---

### Clinical Impact

**Year 7-10** (If Successful):

- Drug approved for AATD liver disease (first-ever treatmentâ€”currently no options except transplant)
- 10,000+ ZZ patients treated (prevent cirrhosis, liver failureâ€”save lives)

**Long-Term** (10-20 years):

- Combination therapy (gene therapy + polymer clearanceâ€”cure both lung and liver disease)
- Reduced need for liver transplant (prevent progression to end-stage liver diseaseâ€”save 100+ lives/year)

---

### Revenue to Foundation

**Licensing Deal** (Year 5-7):

- Upfront + milestones: $30M-$60M (fund Foundation programs for 5-10 years)

**Royalties** (Year 10+):

- Annual royalties: $5M-$20M/year (sustainable funding in perpetuityâ€”assuming $500M-$2B annual drug sales, 1-10% royalty rate)

---

## Summary

**ZZ Protein Recovery = Potential Cure for AATD**:

- âœ… **Novel Approach**: Rescue patient's own protein (vs. replace with donor AATâ€”current therapy)
- âœ… **Treats Liver Disease**: Clear toxic polymers (prevent/reverse cirrhosisâ€”no current treatment)
- âœ… **Reduces Burden**: Oral pill vs. weekly infusions (improve quality of life, reduce cost)
- âœ… **Revenue Stream**: License to pharma (royalties fund Foundation programs forever)

**10-Year Vision**: From discovery â†’ drug approval â†’ cure for AATD liver disease

**"What if we could fix the broken protein instead of replacing it?"**

---

**Support ZZ Protein Research**

**Mark Egly Foundation Research Lab**
ðŸ“§ Email: research@markeglyfoundation.org
ðŸ’Š Clinical Trials: trials@markeglyfoundation.org
ðŸ’° Donate to Research: MarkEglyFoundation.org/Research

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"The cure is inside us. We just need to set it free."_

**â€” Mark Egly Foundation**
